Pharmafile Logo
Pharmafocus logo
Advanced Search

Kymriah

Showing 15 posts of 27 posts found.

kymriah

Novartis unveils new multi-trial data for CAR-T therapy Kymriah in advanced lymphoma

December 7, 2020
Research and Development, Sales and Marketing CAR-T, Kymriah, Novartis

Novartis has taken the opportunity at the 2020 American Society of Hematology Annual Meeting & Exposition (ASH) to unveil promising …

News
kymriah

Novartis’ CAR T therapy Kymriah nails main goal in follicular lymphoma

August 4, 2020
Manufacturing and Production, Research and Development CAR-T therapy, Cancer, Kymriah, Novartis, car t therapy

Novartis is celebrating the success of its one-time CAR T therapy Kymriah (tisagenlecleucel) in patients with relapsed or refractory (r/r) …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

August 16, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Air pollution, CAR-T therapy, HIV, Kymriah, Medicare, Novartis, Yescarta, Zolgensma

Novartis’ faulty data scandal dominated the headlines this week, as the Swiss firm faced fierce backlash over covering up the …

News
101817_tumorsmyeloidsuppressorcells

Medicare will cover CAR-T therapies in United States

August 8, 2019
Sales and Marketing CAR-T therapies, Cancer, Gilead, Kymriah, Medicare, Novartis, keytruda, pharma

Medicare will cover the cost of Novartis’ and Gilead’s CAR-T therapies Kymriah and Yescarta, the US Centers for Medicare and …

News
novartis_window

Novartis’ Kymriah to be covered by Japan’s national insurance system

May 16, 2019
Medical Communications, Sales and Marketing CAR T, CAR-T, Japan, Kymriah, Novartis, pharma

Japan’s national medical insurance system will pay for Novartis’ CAR-T therapy Kymriah following approval from the Central Social Insurance Medical …

News

Scottish Medicines Consortium rejects Novartis’ CAR T therapy Kymriah

March 12, 2019
Manufacturing and Production Kymriah, NICE, Novartis, SMC, Scotland, UK

Scotland’s cost effectiveness body has refused to fund Novartis’ CAR T therapy Kymriah for adult patients with lymphoma. The Scottish …

News
kymriah

Novartis’ CAR-T therapy Kymriah gets NICE green light in diffuse large B-cell lymphoma

February 1, 2019
Medical Communications, Sales and Marketing CAR-T, Cancer, Kymriah, NICE, Novartis, lymphoma, pharma

NICE has announced another momentous decision for lymphoma patients in England and Wales:, recommending Novartis’ chimeric antigen receptor T cell …

News
novartis_window

Canada Health approves Novartis’ CAR-T therapy Kymriah

January 18, 2019
Medical Communications CAR T, CAR-T, Canada, Cancer, Kymriah, Novartis, oncology

Health Canada has approved Novartis’ CAR-T therapy Kymriah for use in paediatric and young adult patients aged between three and …

News

Novartis unveils strong longer-term Kymriah data at ASH 2018

December 3, 2018
Research and Development, Sales and Marketing ASH 2018, Cancer, Kymriah, Novartis, leukaemia, pharma

Novartis has lifted the curtain on longer-term analysis data for its CAR-T therapy Kymriah (tisagenlecleucel) at the American Society of …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

November 23, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Kymriah, Mundipharma, UK, US, brexit, pharma, politics, top 10

The appointment of GSK veteran Arnaud Breabout to the position of Senior Vice President and CFO of Mundipharma took the …

News

Kymriah to be made available in UK for paediatric leukaemia patients via Cancer Drugs Fund

November 15, 2018
Sales and Marketing CAR-T, Cancer, Cancer Drugs Fund, Kymriah, NHS, NICE, leukaemia, pharma

NICE has announced its recommendation that Novartis’ CAR-T cell therapy Kymriah (tisagenlecleucel) be made available in the treatment of relapsed …

News
acute_lymphoblastic_leukaemia_smear

20 year old man died after leukaemia cell was accidently mixed into CAR T therapy

October 2, 2018
Manufacturing and Production CAR T, CAR-T, Cancer, Kymriah, Novartis, leukaemia, oncology

A 20 year old man died after a single leukaemia cell accidentally ended up in a batch of cells that …

News
novartis_window

Novartis strike $40m deal with Chinese firm Cellular Biomedicine

September 28, 2018
Medical Communications CAR T, CAR-T, China, Kymriah, Novartis, cellular biomedicine, prc

Swiss multinational Novartis have paired up with Chinese drugmaker Cellular Biomedicine (CBMG) in order to manufacture CAR-T therapy Kymriah in …

News
white-blood-cell-543471_1920

NICE decision could limit future development of CAR T therapies; Evelyn Warner comments on NICE’s decision making process

September 25, 2018
Research and Development CAR T, CAR-T, Cancer, Duff and Phelps, Kymriah, access, oncology, pricing

Lack of access to CAR T therapies in the United Kingdom could hinder the development of effective personalised cancer treatments, …

News
kymriah

NICE rejects CAR-T therapy Kymriah for DLBCL in adults

September 19, 2018
Research and Development CAR T, CAR-T, Kymriah, NICE, Novartis, leukaemia

The National Institute for health and Care Excellence (NICE) has rejected Novartis’ CAR-T therapy Kymriah for use in adults with …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024